Active	Status	Sponsor type	Region	Phase	Filter
8 Active 3 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tivumecirnon (FLX475) / RAPT Therap
KEYNOTE-B83, NCT04768686: FLX475 Combined with Pembrolizumab in Patients with Advanced or Metastatic Gastric Cancer	Completed	2	20	RoW	FLX475, Pembrolizumab, KEYTRUDA®	Hanmi Pharmaceutical Company Limited, Merck Sharp & Dohme LLC	Gastric Cancer	08/24	08/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab	Completed	1/2	323	US, RoW	FLX475, pembrolizumab (KEYTRUDA®)	RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC	Advanced Cancer	12/24	12/24
zelnecirnon (RPT193) / RAPT Therap
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis	Terminated	2	229	Canada, US	RPT193, Placebo	RAPT Therapeutics, Inc.	Atopic Dermatitis	05/24	05/24
RPT193-03, NCT05935332: Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma	Terminated	2	38	Europe, US, RoW	RPT193, Placebo	RAPT Therapeutics, Inc.	Asthma	06/24	06/24
NCT06087978: Study of RPT193 in Healthy Adult Male Subjects	Completed	1	7	US	14C RPT193	RAPT Therapeutics, Inc.	Healthy Male Subjects	10/23	10/23
JYB1904 / RAPT Therap
NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma	Active, not recruiting	2	69	RoW	JYB1904, Omalizumab	Jemincare	Allergic Asthma	10/25	10/25
NCT06509334: Trial of JYB1904 in Chronic Spontaneous Urticaria.	Recruiting	2	135	RoW	JYB1904, Omalizumab	Jemincare	Chronic Spontaneous Urticaria	07/26	07/26
NCT05449535: Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects	Completed	1	56	RoW	JYB1904, Omalizumab, Xolair, JYB1904 Placebo	Jemincare	Healthy	01/23	01/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tivumecirnon (FLX475) / RAPT Therap
KEYNOTE-B83, NCT04768686: FLX475 Combined with Pembrolizumab in Patients with Advanced or Metastatic Gastric Cancer	Completed	2	20	RoW	FLX475, Pembrolizumab, KEYTRUDA®	Hanmi Pharmaceutical Company Limited, Merck Sharp & Dohme LLC	Gastric Cancer	08/24	08/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab	Completed	1/2	323	US, RoW	FLX475, pembrolizumab (KEYTRUDA®)	RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC	Advanced Cancer	12/24	12/24
zelnecirnon (RPT193) / RAPT Therap
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis	Terminated	2	229	Canada, US	RPT193, Placebo	RAPT Therapeutics, Inc.	Atopic Dermatitis	05/24	05/24
RPT193-03, NCT05935332: Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma	Terminated	2	38	Europe, US, RoW	RPT193, Placebo	RAPT Therapeutics, Inc.	Asthma	06/24	06/24
NCT06087978: Study of RPT193 in Healthy Adult Male Subjects	Completed	1	7	US	14C RPT193	RAPT Therapeutics, Inc.	Healthy Male Subjects	10/23	10/23
JYB1904 / RAPT Therap
NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma	Active, not recruiting	2	69	RoW	JYB1904, Omalizumab	Jemincare	Allergic Asthma	10/25	10/25
NCT06509334: Trial of JYB1904 in Chronic Spontaneous Urticaria.	Recruiting	2	135	RoW	JYB1904, Omalizumab	Jemincare	Chronic Spontaneous Urticaria	07/26	07/26
NCT05449535: Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects	Completed	1	56	RoW	JYB1904, Omalizumab, Xolair, JYB1904 Placebo	Jemincare	Healthy	01/23	01/23